Intriguingly, the authors found that in breast tumor mouse models, intravenous administration of exosomes derived from miR-155–overexpressing tumors augmented the immune response, as characterized by increased CD45+ immune cells and cytotoxic CD8+ T cells in tumor tissues. This evidence concerns the gene PTPRC and neoplasm.